Initial adequate anti-infective therapy is associated with significantly improved clinical outcomes for patients with severe infections. However, in critically ill patients, several pathophysiological and/or iatrogenic factors may affect the pharmacokinetics of anti-infective agents leading to suboptimal drug exposure, in particular during the early phase of therapy. Therapeutic drug monitoring (TDM) may assist to overcome this problem. We discuss the available evidence on the use of TDM in critically ill patient populations for a number of anti-infective agents, including aminoglycosides, β-lactams, glycopeptides, antifungals and antivirals. Also, we present the available evidence on the practices of anti-infective TDM and describe the potential utility of TDM to improve treatment outcome in critically ill patients with severe infections. For aminoglycosides, glycopeptides and voriconazole, beneficial effects of TDM have been established on both drug effectiveness and potential side effects. However, for other drugs, therapeutic ranges need to be further defined to optimize treatment prescription in this setting.
CITATION STYLE
Jager, N. G. L., van Hest, R. M., Lipman, J., Taccone, F. S., & Roberts, J. A. (2016, July 2). Therapeutic drug monitoring of anti-infective agents in critically ill patients. Expert Review of Clinical Pharmacology. Taylor and Francis Ltd. https://doi.org/10.1586/17512433.2016.1172209
Mendeley helps you to discover research relevant for your work.